NurExone partners with Novasign on exosome bioprocess optimization initiative

PUBT · 1d ago
NurExone partners with Novasign on exosome bioprocess optimization initiative
  • NurExone partnered with Austria-based Novasign to model its proprietary exosome production process to support manufacturing scale-up.
  • Initiative targets process optimization, tighter product characterization, lower operating costs, improved efficiency, using predefined KPIs.
  • Work also supports a planned technology transfer of the process to Exo-Top, its wholly owned US subsidiary.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NurExone Biologic Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300829PRIMZONEFULLFEED9800897) on July 30, 2026, and is solely responsible for the information contained therein.